Skip to content
Homepage
Author:
Secura Bio
Posted Date:
April 27, 2026
Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma
Secura Bio
April 27, 2026
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
Secura Bio
February 11, 2026
